Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved..
In the context of chronic myeloid leukemia (CML) resistant to tyrosine kinase inhibitors (TKIs), BCR-ABL1 tyrosine kinase domain (TKD) mutations still remain the sole biological marker that directly condition therapeutic decision. These recommendations aim at updating the use of BCR-ABL1 mutation testing with respect to new available therapeutic options and at repositioning different testing methods at the era of next generation sequencing (NGS). They have been written by a panel of experts from the French Study Group on CML (Fi-LMC), after a critical review of relevant publications. TKD mutation testing is recommended in case of treatment failure but not in case of optimal response. For patients in warning situation, mutation testing must be discussed depending on the type of TKI used, lasting of the treatment, kinetic evolution of BCR-ABL1 transcripts along time and necessity for switching treatment. The kind and the frequency of TKD mutations occasioning resistance mainly depend on the TKI in use and disease phase. Because of its better sensitivity, NGS methods are recommended for mutation testing rather than Sanger's. Facing a given TKD mutation, therapeutic decision should be taken based on in vitro sensitivity and clinical efficacy data. Identification by sequencing of a TKD mutation known to induce resistance must lead to a therapeutic change. The clinical value of testing methods more sensitive than NGS remains to be assessed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 107(2020), 1 vom: 17. Jan., Seite 113-128 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations du France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) pour l’examen des mutations du domaine kinase de BCR-ABL1 dans la leucémie myéloïde chronique |
|---|
| Beteiligte Personen: |
Cayuela, Jean-Michel [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.02.2020 Date Revised 27.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bulcan.2019.05.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299648079 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299648079 | ||
| 003 | DE-627 | ||
| 005 | 20231225100806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2019.05.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0998.xml |
| 035 | |a (DE-627)NLM299648079 | ||
| 035 | |a (NLM)31353136 | ||
| 035 | |a (PII)S0007-4551(19)30259-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Cayuela, Jean-Michel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia |
| 246 | 3 | 3 | |a Recommandations du France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) pour l’examen des mutations du domaine kinase de BCR-ABL1 dans la leucémie myéloïde chronique |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2020 | ||
| 500 | |a Date Revised 27.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a In the context of chronic myeloid leukemia (CML) resistant to tyrosine kinase inhibitors (TKIs), BCR-ABL1 tyrosine kinase domain (TKD) mutations still remain the sole biological marker that directly condition therapeutic decision. These recommendations aim at updating the use of BCR-ABL1 mutation testing with respect to new available therapeutic options and at repositioning different testing methods at the era of next generation sequencing (NGS). They have been written by a panel of experts from the French Study Group on CML (Fi-LMC), after a critical review of relevant publications. TKD mutation testing is recommended in case of treatment failure but not in case of optimal response. For patients in warning situation, mutation testing must be discussed depending on the type of TKI used, lasting of the treatment, kinetic evolution of BCR-ABL1 transcripts along time and necessity for switching treatment. The kind and the frequency of TKD mutations occasioning resistance mainly depend on the TKI in use and disease phase. Because of its better sensitivity, NGS methods are recommended for mutation testing rather than Sanger's. Facing a given TKD mutation, therapeutic decision should be taken based on in vitro sensitivity and clinical efficacy data. Identification by sequencing of a TKD mutation known to induce resistance must lead to a therapeutic change. The clinical value of testing methods more sensitive than NGS remains to be assessed | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ABL1 inhibitors | |
| 650 | 4 | |a ABL1 tyrosine kinase domain mutations | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a Inhibiteurs d’ABL1 | |
| 650 | 4 | |a Leucémie myéloïde chronique | |
| 650 | 4 | |a Mutations du domaine tyrosine kinase d’ABL1 | |
| 650 | 4 | |a Resistance | |
| 650 | 4 | |a Résistance | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a BCR-ABL1 fusion protein, human |2 NLM | |
| 650 | 7 | |a DNA, Neoplasm |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Fusion Proteins, bcr-abl |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Chomel, Jean-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Coiteux, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Dulucq, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Escoffre-Barbe, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Etancelin, Pascaline |e verfasserin |4 aut | |
| 700 | 1 | |a Etienne, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Hayette, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Millot, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Nibourel, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolini, Franck-Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Réa, Delphine |e verfasserin |4 aut | |
| 700 | 0 | |a pour la France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) et le Groupe des biologistes moléculaires des hémopathies malignes (GBMHM) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 107(2020), 1 vom: 17. Jan., Seite 113-128 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2020 |g number:1 |g day:17 |g month:01 |g pages:113-128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2019.05.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2020 |e 1 |b 17 |c 01 |h 113-128 | ||